Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Proliferative Diabetic Retinopathy (PDR) Market Size from 2025 to 2034?
The market size for proliferative diabetic retinopathy (pdr) has been expanding quickly in the last few years. Starting at $2.42 billion in 2024, it’s projected to climb up to $2.69 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 11.3%. The growth observed in the historical period can be credited to increasing rates of diabetes, alterations in lifestyle choices and consumption of unhealthy food, governmental programs, and the escalating cases of vision loss connected to diabetes.
The market for proliferative diabetic retinopathy (pdr) is forecasted to expand significantly in the upcoming years, surging to$4.03 billion in 2029″ at a compound annual growth rate (CAGR) of 10.6%. The anticipated growth in the coming period is linked to factors such as an aging demographic, increased public knowledge and education regarding diabetes, funding for research and development, and a growing demand for combination therapies. Key trends during the forecast period will be progress in diagnostic technologies, novel therapeutic options, the use of artificial intelligence (AI) in early diagnosis, advancements in gene therapy, and high-tech retinal imaging.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Proliferative Diabetic Retinopathy (PDR) Market?
The increasing occurrence of diabetes is anticipated to drive the proliferative diabetic retinopathy (PDR) market’s expansion. Diabetes, a chronic health condition characterized by high blood sugar levels, is the primary cause of PDR. Various treatments can mitigate further retinal damage and maintain vision. The National Health Service (NHS), a UK government department, reported a significant rise in diabetes cases among under-40s, from 173,166 in 2022 to 216,440 in 2023. This substantial increase raises worries about this age group. The data echoes the swift increase in diabetes occurrence among younger demographics. Thus, the escalating prevalence of diabetes is propelling the PDR market.
Which Primary Segments of the Proliferative Diabetic Retinopathy (PDR) Market Are Driving Growth and Industry Transformations?
The proliferative diabetic retinopathy (pdr)market covered in this report is segmented –
1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy; Intraocular Steroids; Laser Surgery; Vitrectomy
2) By Mode of Administration: Injectables; Oral; Other Mode Of Administrations
3) By Application: Hospitals; Clinics; Other Applications
Subsegments:
1) By Anti-VEGF Therapy: Aflibercept; Ranibizumab; Bevacizumab
2) By Intraocular Steroids: Triamcinolone Acetonide; Dexamethasone Implant; Fluocinolone Acetonide
3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Laser Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy; Anterior Vitrectomy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12911&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Proliferative Diabetic Retinopathy (PDR) Market?# Market?
North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Are the Most Significant Market Trends in the Proliferative Diabetic Retinopathy (PDR) Market?
Key players in the proliferative diabetic retinopathy market are consistently striving to develop innovative therapies to augment the efficacy of treatments, lessen the stress of treatments and enhance the results for patients. Take for instance, in June 2022, Biogen, an American biotech company, and Samsung Bioepis, a South Korean biotech company, launched Byooviz (ranibizumab-nuna), which is the first biosimilar in the field of ophthalmology in the US. These new offerings are utilised in the treatment of patients suffering from diabetic macular edema, proliferative diabetic retinopathy, wet age-related macular degeneration (wet AMD), and choroidal neovascularization.
View the full report here:
What Parameters Are Used to Define the Proliferative Diabetic Retinopathy (PDR) Market?
Proliferative diabetic retinopathy (PDR) refers to an advanced stage of diabetic eye disease characterized by the growth of abnormal blood vessels in the retina due to prolonged high blood sugar levels. These vessels can lead to retinal bleeding, scarring and vision impairment if left untreated, making regular eye examinations crucial for early detection and management.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
